3 Ultra-High-Growth Biopharma Stocks to Grab Now
Biotech has outpaced nearly every other sector this year in growth. While the S&P 500 was down 3.6% for the year as of Wednesday, the NASDAQ Biotechnology Index (NBI) is up 10.5% in 2020. That growth carries an enormous amount of risk, however, as many biotech companies aren't making profits and are burning through cash while searching for drugs that will turn things around.
Here are three promising biotechs that stand out and whose share prices have been climbing this year because of positive clinical trials.
Shares in Sarepta Therapeutics (NASDAQ: SRPT) have climbed 26.6% so far in 2020.
Source Fool.com
